BeiGene Ltd ADR Stock
Price
Target price
€180.00
€180.00
1.110%
2.0
1.110%
€272.64
25.09.23 / Tradegate
WKN: A1437N / Symbol: BGNE / Name: BeiGene / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
BeiGene Ltd ADR Stock
There is an upward development for BeiGene Ltd ADR compared to yesterday, with an increase of €2.00 (1.110%).
Currently there is a rather positive sentiment for BeiGene Ltd ADR with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 272 € shows a very positive potential of 51.11% compared to the current price of 180.0 € for BeiGene Ltd ADR.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for BeiGene Ltd ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of BeiGene Ltd ADR in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of BeiGene Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| BeiGene Ltd ADR | 1.110% | -4.255% | -3.743% | 16.129% | -14.286% | -26.230% | - |
| Atara Biotherapeutics Inc. | -6.800% | 11.525% | 11.404% | -55.403% | -48.013% | -86.138% | - |
| Brainstorm Cell | -32.030% | -56.809% | -73.806% | -89.375% | -71.368% | -96.853% | - |
| Inovio Pharma | 4.420% | -4.497% | -9.296% | -79.354% | -74.552% | -97.510% | -90.930% |
Comments
BeiGene, Ltd. (NASDAQ: BGNE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $259.00 price target on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Morgan Stanley from $321.00 to $319.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $297.00 to $300.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
